SCHEMBL5543447

SCHEMBL5543447

[CH2]c1nc(-c2cccc(F)c2)oc1C

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SLC9A1 P19634 1/20 0.48
MAOB P27338 2/20 0.48
NOTUM Q6P988 2/20 0.45
TP53 P04637 1/20 0.43
HPN P05981 1/20 0.43
KDM4E B2RXH2 1/20 0.42
GUSB P08236 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
TRPM8 Q7Z2W7 1/20 0.41
KDM1A O60341 1/20 0.41
GRM5 P41594 1/20 0.40
UTRN P46939 2/20 0.40
MGAM O43451 1/20 0.39
GAA P10253 1/20 0.39
SI P14410 1/20 0.39
MGAM2 Q2M2H8 1/20 0.39
PPARG P37231 1/20 0.39
PPARA Q07869 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5539637 0.83 MAOB (0.50) SLC9A1MAOBNOTUMTP53HPN
SCHEMBL5536092 0.81 NPC1 (0.50) SLC9A1MAOBNOTUMTP53
SCHEMBL5539633 0.81 MAOB (0.48) SLC9A1MAOBNOTUMTP53HPN
SCHEMBL5543992 0.80 NPC1 (0.48) NOTUMTP53KDM4EGUSBL3MBTL1
SCHEMBL3758086 0.79 KDM4E (0.51) SLC9A1KDM4EGAA
SCHEMBL12163868 0.77 KDM4E (0.50) SLC9A1MAOBHPNKDM4EKDM1A
SCHEMBL4830084 0.77 KDM4E (0.50) SLC9A1MAOBNOTUMHPNKDM4E
SCHEMBL1805427 0.76 BRD4 (0.55) SLC9A1NOTUMKDM4EKDM1APPARG
SCHEMBL1805429 0.75 KDM1A (0.42) KDM4EKDM1A
SCHEMBL6509332 0.75 PPARG (0.52) SLC9A1KDM4EKDM1APPARGPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
CN-101255170-A 2,3-dihydroimidazo[2,1-b]oxazole compound OTSUKA PHARMA CO LTD (JP) 2008-09-03 CN disclosed
CN-101172981-A 2,3-dihydroimidazo[2,1-b]oxazole compound OTSUKA PHARMA CO LTD (JP) 2008-05-07 CN disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
CN-1705670-A 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds OTSUKA PHARMA CO LTD (JP) 2005-12-07 CN disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 SLC9A1 2413/4885MAOB 2140/4885NOTUM 3827/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.